Rps23rg1, identified as ribosomal protein S23, retrogene 1, stands as a pivotal component in cellular processes, contributing to adenylate cyclase binding activity and serving as an intrinsic membrane element. Its functional spectrum encompasses acting both upstream and within the amyloid-beta metabolic process, where it negatively regulates protein metabolic processes and positively influences protein kinase A (PKA) signaling. This multifaceted role underscores Rps23rg1's significance in the intricate orchestration of cellular activities, emphasizing its involvement in key signaling pathways critical for cellular function. In the context of inhibition, understanding the regulatory mechanisms that dampen Rps23rg1's activity provides crucial insights into cellular dynamics. The inhibition of Rps23rg1 could be achieved through various means, including interference with adenylate cyclase binding activity. Disrupting this binding might hinder downstream signaling events, subsequently impacting the intricate balance between positive and negative regulatory processes governed by Rps23rg1. Moreover, negative regulation of protein metabolic processes by Rps23rg1 could be inhibited, potentially leading to dysregulation within the cellular environment. Mechanisms targeting this negative regulation might involve blocking or altering specific pathways or components that Rps23rg1 engages with during this process. Additionally, inhibiting the positive regulation of PKA signaling by Rps23rg1 could disrupt the normal cellular response to various stimuli, affecting downstream processes influenced by PKA activity.
General mechanisms of inhibition might involve targeting key nodes within the pathways in which Rps23rg1 operates. For instance, inhibiting the upstream components that lead to adenylate cyclase binding activity could effectively impede Rps23rg1's activation cascade. Similarly, interfering with the membrane integration of Rps23rg1 might disrupt its intrinsic role in cellular membranes, potentially impacting its functions. Inhibition strategies could be directed towards modulating the intricate network of interactions involving Rps23rg1, influencing its engagement with key cellular processes. While the specific biochemical details of inhibition may vary, a comprehensive understanding of Rps23rg1's functions provides a foundation for exploring potential avenues for targeted disruption of its activities within the cell. Continued research into the mechanisms and consequences of inhibiting Rps23rg1 contributes to the broader understanding of cellular regulation and opens avenues for exploring novel strategies to modulate cellular activities.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor, affecting the EGFR signaling pathway. It indirectly influences Rps23rg1 by disrupting the downstream events of EGFR signaling, where Rps23rg1 is interconnected. The alteration in this cascade impacts the function of Rps23rg1. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor affecting protein degradation. It influences Rps23rg1 by altering the stability of proteins involved in signaling pathways connected to Rps23rg1. The disruption of protein homeostasis impacts the function of Rps23rg1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a dual Bcr-Abl/Src kinase inhibitor. Through inhibition of Src kinase, it influences downstream signaling pathways, including Ras/MAPK. This indirect modulation impacts Rps23rg1, which is connected to the Ras/MAPK pathway, resulting in altered dynamics of Rps23rg1. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a JAK1/2 inhibitor affecting the JAK/STAT signaling pathway. As Rps23rg1 is associated with the STAT pathway, Ruxolitinib indirectly inhibits Rps23rg1 by disrupting this signaling cascade. The interference in the pathway dynamics impacts the function of Rps23rg1. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor, primarily affecting RAF/MEK/ERK signaling. By impeding this pathway, it indirectly modulates Rps23rg1, which interacts with components of the ERK cascade. The inhibition disrupts the normal course of events, affecting Rps23rg1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3-kinase inhibitor affecting the PI3K/Akt pathway. Rps23rg1 interacts with components of this pathway, and LY294002 disrupts it, leading to indirect inhibition of Rps23rg1 by altering the signaling dynamics in the PI3K/Akt pathway. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets both EGFR and HER2. It hinders the downstream signaling of these receptors, particularly in the Ras/MAPK pathway, indirectly influencing Rps23rg1 by disrupting the cascading signaling events. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a MEK1/2 inhibitor, disrupting the Ras/Raf/MEK/ERK pathway. Rps23rg1 interacts with components of this pathway, and Selumetinib indirectly inhibits Rps23rg1 by altering the signaling dynamics. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 is a Bcl-2 inhibitor, affecting apoptosis regulation. It indirectly influences Rps23rg1 by modulating the apoptotic pathway, where Rps23rg1 has been implicated. The disruption of apoptosis dynamics leads to an indirect inhibition of Rps23rg1. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor targeting Bcr-Abl and c-Kit. It indirectly influences Rps23rg1 by inhibiting the downstream signaling of Bcr-Abl, which is connected to the Ras/MAPK pathway. | ||||||